Biomedical Engineering Reference
In-Depth Information
• h erefore, apoC-III can be a new therapeutic target to prevent coronary
heart disease in patients with dysmetabolic states.
Abbreviations
apoB
apolipoprotein B
ApoC-III
apolipoprotein C-III
EC
endothelial cells
eNOS
endothelial nitric oxide synthase
HDL
high density lipoprotein
HSVEC
human saphenous vein endothelial cells
HUVEC
human umbilical vein endothelial cells
ICAM-1
intercellular adhesion molecule 1
LDL
low density lipoprotein
MyD88
myeloid dif erentiation primary response gene 88
NF-κB
nuclear factor κB
NO
nitric oxide
oxLDL
oxidized low density lipoproteins
PKC
protein kinase C
PTX
pertussis toxin
RLP
remnant lipoprotein
TLR
toll-like receptor
VCAM-1
vascular cell adhesion molecule 1
VLDL
very low density lipoprotein
Key Facts about Apolipoproteins
1. Apolipoproteins are protein constituents of lipoproteins, carriers of lipids
in circulation.
(a) Apolipoprotein(apo) B is the structural protein for apoB lipoproteins,
including VLDL, IDL and LDL.
(b) ApoA-I is the main structural protein for HDL. ApoA-I may possess
direct anti-inl ammatory and anti-atherogenic activities, at least in
part through the inhibition of adhesion molecule expression.
2. ApoC-III is a small apolipoprotein present mainly on triglyceride-rich
lipoproteins (VLDL, IDL) and HDL.
(a) ApoC-III inhibits apoB lipoprotein clearance by interfering with apoB-
or apoE-mediated receptor binding.
